New phase 3 trial data confirm the uniquely high efficacy and good safety profile of the R21/Matrix-M malaria vaccine in African children

The R21/Matrix-M vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. R21/Matrix-M vaccine was well tolerated, with injection site pain and fever as the most frequent adverse events. Our collaboration with the University of Oxford has been instrumental in developing the R21/Matrix-M™ malaria vaccine. Professor Alassane Dicko, Principal Investigator in Mali of the R21/Matrix-M vaccine said “It has been very exciting to generate high efficacy data with the new R21/Matrix-M vaccine so quickly. The R21/Matrix-M Phase 3 efficacy data published in The Lancet reinforce the potential of R21/Matrix-M vaccine to protect children against this disease.